scholarly journals Vitamin D, Cognition and Alzheimer’s Disease: The Therapeutic Benefit is in the D-Tails

2016 ◽  
Vol 53 (2) ◽  
pp. 419-444 ◽  
Author(s):  
Véréna Landel ◽  
Cédric Annweiler ◽  
Pascal Millet ◽  
Maria Morello ◽  
François Féron
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vitamin D ◽  
Therapeutic Benefit

Vitamin-D-Free Regimen Intensifies the Spatial Learning Deficit in Alzheimer's Disease

2011 ◽  
Vol 121 (1) ◽  
pp. 16-24 ◽  
Author(s):  
Mohsen Taghizadeh ◽  
Abolghassem Djazayery ◽  
Mahmoud Salami ◽  
Mohammad Reza Eshraghian ◽  
Sayyed Alireza Talaei Zavareh
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vitamin D ◽  
Spatial Learning ◽  
Learning Deficit

Vitamin D in the Development and Progression of Alzheimer’s Disease: Implications for Clinical Management

2021 ◽  
Author(s):  
Francesco Panza ◽  
Maddalena La Montagna ◽  
Luisa Lampignano ◽  
Roberta Zupo ◽  
Ilaria Bortone ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vitamin D ◽  
Clinical Management

scholarly journals P1-345: Role of Vitamin D Signaling in Sporadic Alzheimer’s Disease: A Clinico-Experimental Study

2016 ◽  
Vol 12 ◽  
pp. P561-P562
Author(s):  
Anindita Banerjee ◽  
Vineet Kumar Khemka ◽  
Debashree Roy ◽  
Aparajita Dhar ◽  
Tapan Kumar Sinha Roy ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Experimental Study ◽  
Vitamin D ◽  
Sporadic Alzheimer’S Disease ◽  
Vitamin D Signaling

P1-068: Association between vitamin D binding protein (VDBP) haplotype and late-onset Alzheimer's disease

2013 ◽  
Vol 9 ◽  
pp. P177-P177
Author(s):  
Omur Selin Araz ◽  
Erdinc Dursun ◽  
Duygu Gezen-Ak ◽  
Hasmet Hanagasi ◽  
Basar Bilgiç ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vitamin D ◽  
Late Onset ◽  
Binding Protein ◽  
Vitamin D Binding Protein

P3-328: Alzheimer's disease psychosis: Potential therapeutic benefit of pimavanserin, a 5-HT2A inverse agonist

2010 ◽  
Vol 6 ◽  
pp. S548-S548
Author(s):  
Krista McFarland ◽  
Diana L. Price ◽  
Sean A. Gorman ◽  
Robert W. Johnson ◽  
Douglas W. Bonhaus
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Therapeutic Benefit ◽  
Inverse Agonist ◽  
Potential Therapeutic Benefit

scholarly journals ESTUDO DE POLIMORFISMOS NO GENE RECEPTOR DA VITAMINA D EM PACIENTES COM A DOENÇA DE ALZHEIMER/ STUDY OF POLYMORPHISMS IN THE VITAMIN D RECEPTOR GENE IN PATIENTS WITH ALZHEIMER'S DISEASE

2020 ◽  
Vol 6 (12) ◽  
pp. 94546-94554
Author(s):  
Higor Vinicius Alves do Nascimento ◽  
André dos Santos Costa ◽  
Maria de Mascena Diniz Maia ◽  
Paulo Daywson Lopes da Silva ◽  
Luiz Paulo de Souza Prazeres ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vitamin D ◽  
Vitamin D Receptor ◽  
Receptor Gene ◽  
Vitamin D Receptor Gene ◽  
Vitamina D

scholarly journals Serum vitamin D in patients with mild cognitive impairment and Alzheimer's disease

2018 ◽  
Vol 8 (3) ◽  
pp. e00936 ◽  
Author(s):  
Shinji Ouma ◽  
Midori Suenaga ◽  
Funda F. Bölükbaşı Hatip ◽  
Izzettin Hatip-Al-Khatib ◽  
Yoshio Tsuboi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vitamin D ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Serum Vitamin ◽  
Serum Vitamin D

scholarly journals Therapeutic benefit of aripiprazole-olanzapine combination in the treatment of senile Alzheimer’s disease complicated by mental disorders

2020 ◽  
Vol 19 (2) ◽  
pp. 441-446
Author(s):  
Na Zheng ◽  
Ning Wang ◽  
Ji-Min Jia
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mental Disorders ◽  
Clinical Efficacy ◽  
Lower Incidence ◽  
Adverse Reactions ◽  
Study Groups ◽  
Therapeutic Benefit ◽  
Control Group ◽  
Study Group

Purpose: To determine the clinical efficacy of aripiprazole-olanzapine combination treatment in elderly Alzheimer’s disease complicated with mental disorders. Methods: Ninety-two elderly patients with Alzheimer’s disease and mental disorders who were admitted to Binzhou People's Hospital, were enrolled in the study. They were randomized into control and study groups. Control group was treated with olanzapine, while the study group was treated with aripiprazole as an adjuvant therapy in addition to olanzapine. The clinical efficacy, scores on different scales (MMSE, ADAS-cog, CDR, ADL, NPI and CMAI), and incidence of adverse reactions were determined. Results: The overall degree of response was significantly higher in the study group than in the control group (p < 0.05). There were no significant differences in MMSE, ADAS-cog, CDR, ADL, NPI and CMAI scores between the two groups before treatment (p > 0.05). The MMSE score of the study group was significantly higher than that of the control group, and the scores in the other scales in the study group were significantly lower after treatment (p < 0.05). The study group had significantly lower incidence of adverse reactions than control group (p < 0.05). Conclusion: Aripiprazole-olanzapine combination has significant therapeutic benefit in the treatment of elderly Alzheimer’s disease patients complicated with mental disorders. It promotes recovery of neurological function, as well as produces a lower incidence of adverse reactions. Keywords: Aripiprazole, Olanzapine, Alzheimer’s disease, Mental disorders

Sign in / Sign up

Export Citation Format

Share Document